人類胰島素市場規模、佔有率和成長分析（按產品、類型、品牌、給藥裝置、糖尿病類型和地區分類）－2026-2033年產業預測

預計到 2024 年，人類胰島素市場規模將達到 202.8 億美元，到 2025 年將達到 212.3 億美元，到 2033 年將達到 306.6 億美元，預測期（2026-2033 年）的複合年成長率為 4.7%。

人類胰島素市場是糖尿病治療的關鍵組成部分，為數百萬1型和第2型糖尿病患者提供必要的治療並改善其生活品質。隨著全球糖尿病盛行率的上升，預計胰島素需求將顯著成長。生產技術的創新，特別是重組DNA技術，推動了更安全、更純淨胰島素的研發，提高了病患的接受度並擴大了市場。醫療機構和政府為提高公眾意識和改善胰島素可及性而進行的合作對於推動市場需求至關重要。然而，高成本和複雜的監管阻礙了胰島素的普及，尤其是在低收入地區。速效胰島素類似物的發展趨勢和胰島素輸注裝置的進步也在重塑市場未來，有助於提高治療效果和病患依從性。

人類胰島素市場促進因素

全球糖尿病發生率的不斷上升是推動人類胰島素市場發展的主要因素。隨著越來越多的患者被診斷出患有糖尿病，對胰島素等有效治療方案的需求也顯著成長。糖尿病病例的增加通常與生活方式和飲食習慣的改變有關，尤其是在都市化加快、加工食品消費量不斷增加的快速發展的發展中國家。因此，糖尿病盛行率上升的地區對人類胰島素的需求也隨之增加，以有效控制病情。這一持續趨勢凸顯了創新胰島素療法的緊迫性，並進一步鞏固了該市場的重要性。

限制人類胰島素市場的因素

人類胰島素市場面臨諸多限制因素，阻礙了市場進入和競爭。其中一個主要障礙是監管環境，新型胰島素產品和生物相似藥的核准需要進行廣泛的測試並嚴格遵守相關指南。這種複雜的核准流程可能會延緩創新治療方法的上市。此外，某些胰島素製劑的專利獨佔權限制了學名藥的生產，減少了病患的選擇。由於長效胰島素類似物受專利保護，這種限制會阻礙市場擴張和可近性，進一步抑制生物相似藥的出現，最終影響市場動態。

人類胰島素市場趨勢

由於胰島素類似物相較於傳統人類胰島素具有諸多優勢，人類胰島素市場正經歷著向胰島素類似物方向的重大轉變。這項轉變的驅動力在於人們對改善血糖控制的需求日益成長，而胰島素類似物則起效迅速、作用持續時間短，能夠更有效地管理糖尿病。醫護人員和患者越來越意識到長效胰島素類似物（如Insulin Glargine和Insulin Detemir）的益處，這些產品憑藉其優異的藥物動力學特性，正佔據著顯著的市場佔有率。這一趨勢預示著，在日益成長的最佳化患者治療效果的需求下，人們正朝著更有效率的糖尿病治療方案轉變。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球人類胰島素市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 人類胰島素製劑
• 人類胰島素輸注裝置

全球人類胰島素市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 胰島素類似物和生物相似藥
  • 快速起效
  • 長效
  • 預混合料
• HI生物製劑
  • 短效
  • 中間作用類型
  • 預混合料

全球人類胰島素市場規模（按品牌和複合年成長率分類）（2026-2033 年）

• 人類胰島素類似物和生物相似藥
  • 來得時
  • 諾和銳/諾和銳
  • Humalog
  • 其他品牌
• 人類胰島素生技藥品
  • Actrapid、Inslatard、Mixtard
  • 優泌林
  • 因蘇曼

全球人類胰島素市場規模（按給藥裝置和複合年成長率分類）（2026-2033 年）

• 筆型
  • 可重複使用類型
  • 一次性的
• 筆針
  • 標準
  • 安全
• 注射器

全球人類胰島素市場規模（依糖尿病及複合年成長率分類）（2026-2033 年）

• 1型糖尿病
• 2型糖尿病

全球人類胰島素市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Biocon Limited（India）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Boehringer Ingelheim（Germany）
• Tonghua Dongbao Pharmaceutical Co., Ltd.（China）
• Wockhardt（India）
• Julphar（United Arab Emirates）
• Oramed Pharmaceuticals Inc.（United States）
• Adocia（France）
• MannKind Corporation（United States）
• Gan & Lee Pharmaceuticals（China）
• Ypsomed（Switzerland）
• Medtronic（Ireland）
• Dexcom（United States）
• Insulet Corporation（United States）
• Senseonics Holdings, Inc.（United States）

結論與建議

Human Insulin Market size was valued at USD 20.28 Billion in 2024 and is poised to grow from USD 21.23 Billion in 2025 to USD 30.66 Billion by 2033, growing at a CAGR of 4.7% during the forecast period (2026-2033).

The human insulin market is a vital component of diabetes care, providing essential treatment for millions affected by type 1 and type 2 diabetes while enhancing their quality of life. With the rising prevalence of diabetes globally, demand for insulin is anticipated to grow significantly. Innovations in production, particularly through recombinant DNA technology, have led to the creation of safer, purer forms of insulin, resulting in increased patient acceptance and market expansion. Collaborative efforts among healthcare organizations and governments to raise awareness and improve access are crucial in driving market demand. However, high costs and complex regulations hinder affordability, particularly in low-income areas. Trends favoring rapid-acting analogs and advancements in insulin delivery devices are also shaping the market's future trajectory, enhancing treatment efficacy and patient adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Insulin Market Segments Analysis

Global Human Insulin Market is segmented by Product, Type, Brand, Delivery Devices, Diabetes and region. Based on Product, the market is segmented into HI Drugs and HI Delivery Devices. Based on Type, the market is segmented into Insulin Analogs and Biosimilars and HI Biologics. Based on Brand, the market is segmented into HI Analogs and Biosimilars and HI Biologics. Based on Delivery Devices, the market is segmented into Pens, Pen Needles and Syringes. Based on Diabetes, the market is segmented into Type I Diabetes and Type II Diabetes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Human Insulin Market

The increasing global incidence of diabetes is a key factor propelling the human insulin market. As more individuals are diagnosed with diabetes, the need for effective management solutions such as insulin rises significantly. This uptick in diabetes cases is often linked to shifts in lifestyle and dietary choices, particularly in rapidly developing nations where urbanization and processed food consumption are on the rise. Consequently, regions experiencing rising diabetes prevalence demonstrate a heightened demand for human insulin to help manage the condition effectively. This ongoing trend underscores the urgency for innovative insulin therapies and reinforces the importance of this market.

Restraints in the Human Insulin Market

The human insulin market faces several restraints that impede market entry and competition. One significant barrier is the regulatory landscape, which requires extensive testing and adherence to strict guidelines to secure approval for new insulin products or biosimilars. This complex approval process can delay the introduction of innovative treatments. Moreover, patent exclusivity surrounding specific insulin formulations restricts the production of generic alternatives, resulting in fewer choices for patients. This limitation can hinder market expansion and accessibility, as the presence of long-acting insulin analogs under patent protection further curtails the emergence of biosimilars, ultimately affecting overall market dynamics.

Market Trends of the Human Insulin Market

The human insulin market is experiencing a significant shift towards analog insulin, driven by the advantages these products provide over traditional human insulin. This transition is fueled by the growing demand for enhanced glycemic control, as analog insulins are associated with faster onset and shorter durations of action, leading to more effective diabetes management. Healthcare providers and patients are increasingly recognizing the benefits of long-acting analogs like insulin glargine and insulin detemir, which are capturing substantial market share due to their superior pharmacokinetics. This trend indicates a broader movement towards more efficient diabetes treatment options as the need for optimized patient outcomes rises.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Insulin Market Size by Product & CAGR (2026-2033)

• Market Overview
• HI Drugs
• HI Delivery Devices

Global Human Insulin Market Size by Type & CAGR (2026-2033)

• Market Overview
• Insulin Analogs and Biosimilars
  • Rapid-acting
  • Long-acting
  • Premixed
• HI Biologics
  • Short-acting
  • Intermediate-acting
  • Premixed

Global Human Insulin Market Size by Brand & CAGR (2026-2033)

• Market Overview
• HI Analogs and Biosimilars
  • Lantus
  • NovoRapid/Novolog
  • Humalog
  • Other Brands
• HI Biologics
  • Actrapid, Insulatard, and Mixtard
  • Humulin
  • Insuman

Global Human Insulin Market Size by Delivery Devices & CAGR (2026-2033)

• Market Overview
• Pens
  • Reusable
  • Disposable
• Pen Needles
  • Standard
  • Safety
• Syringes

Global Human Insulin Market Size by Diabetes & CAGR (2026-2033)

• Market Overview
• Type I Diabetes
• Type II Diabetes

Global Human Insulin Market Size & CAGR (2026-2033)

• North America (Product, Type, Brand, Delivery Devices, Diabetes)
  • US
  • Canada
• Europe (Product, Type, Brand, Delivery Devices, Diabetes)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Brand, Delivery Devices, Diabetes)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Brand, Delivery Devices, Diabetes)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Brand, Delivery Devices, Diabetes)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations